well said. We all try to be fair but fairness is in the ear of the listener not the mouth of the speaker. Forgive the euphemism. It all comes down to temporal frames in a speculative bio. Don't ever expect what is projected to be so. Year end 2016 is 6 1/2 months away. Save your anger (and blood pressure) till then. You might be pleasantly surprised. Share price is in the hands of the market makers. Always was, always will be. Retail is only along for t he ride and never get to exit
a conundrum for sure. If he closes his mouth you complain he doesn't say enough to keep shareholders informed and advance the share price and if he opens it you criticize when something doesn't occur on day and time (give or take a few minutes) he targeted.I prefer he talks and explains why his time frames are off.
for a guy/gal with a handle biotrader to question funding and dilution in a speculative early stage biotech or biopharm with no revenue source suggests perhaps you know little about such companies. Of course I don't prefer companies with endless funding. Unnecessary dilution? Based on what inside info do you make that claim? Is it FDA approved? We're not talking diabetes or migraine here. The potential patient population is limited as is let alone by admission criteria. How many complete thoracic cord injuries to date? You don't know. You take averages you find on he internet. maybe, thank God, it's a slow year for cord injuries. Perhaps you think it best to enroll and fail so you can move on?
doctors deal with death 24/7/365. Not an issue at all. The company has a duty to devise and execute a plan in a reasonable and safe manner. Any investor impatience with time frames are neither concerning nor relevant. Speculatives should be bought with a 7 year event horizon. S**t or get off the pot refers to your investment strategy, not their timeline.
Standing with braces no a big deal. Walking with them, a very big deal. Not only a functioning muscle to propel but one that moves the weight of the limb AND of the brace. Strength = dystrophin. and it matters not how much.
Criminal behavior rampant with blessing of SEC. Retail gets screwed regardless of sector but this discount is reflective of a management that needs to be investigated. but by whom?
so with the price at 21.64 are hey telling there clients to short with an upgrade? lol
Business as usual for speculative bios. Price action indicates news shortly. odds are positive and run to next price level. have a plan in place if you're a trader. good accumulation price if you're building a core.
it will close above 18 and perhaps reach 40 but imo, not in two weeks but upon approval.
only 21.4% are incomplete thoracic lesions. A smaller percentage are true candidates based on admission criteria.
I always thought that for certain drugs such as this the Feds should have a separate category and upon approval should reimburse the company all costs associated with development and then set the price to the patient and insurance companies. Since all costs are recouped any sales become profit and that should be shared with the feds on something like a 75%-25% split (company-feds). That makes drug discovery for these types affordable and worth the time, money and hassle, post approval access and cost very affordable and helps fund similar future research. In fact if the gov gets revenue from it you might see a more sane approval process. Of course it's the government so like Social security there would be no lock on the lock box.